title: Low rates of heterotopic ossification after resurfacing hip arthroplasty with use of prophylactic radiotherapy in select patients.
abstract: Recent reports have noted higher rates of heterotopic ossification (HO) with surface replacement arthroplasty (SRA) than with traditional total hip arthroplasty in the absence of postoperative HO prophylaxis. This study reports rates and grades of HO in 44 SRA patients with at least 1 year of follow-up. Heterotopic ossification prophylaxis was used in 32 (73%) of 44 cases. Heterotopic ossification prophylaxis consisted of radiotherapy (22/32), nonsteroidal anti-inflammatory drugs (8/32), or both (2/32). One case of clinically significant HO was documented in the no-prophylaxis group. This strategy of selective HO prophylaxis in patients felt by orthopedic surgeons to be at high risk of HO resulted in low rates of clinically relevant HO after SRA (1/44, 2.3%). Further study is needed to establish optimal selection criteria for HO prophylaxis after SRA.
authors.affiliation: Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
authors.forename: Tim J
authors.initials: TJ
authors.lastname: Kruser
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Kozak
authors.forename: Donald M
authors.initials: DM
authors.lastname: Cannon
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Platta
authors.forename: John P
authors.initials: JP
authors.lastname: Heiner
authors.forename: Richard L
authors.initials: RL
authors.lastname: Illgen
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D000068579:Celecoxib; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009999:Ossification, Heterotopic / Q000453:epidemiology* / Q000517:prevention & control*; D015207:Osteoarthritis, Hip / Q000601:surgery*; D011720:Pyrazoles / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods*; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D007213:Indomethacin